QT Imaging Holdings’ Technology Advances Medical Imaging Research at the University of Oklahoma’s Health Stephenson Cancer Center

Rhea-AI Summary

QT Imaging Holdings (NASDAQ:QTI) has partnered with the University of Oklahoma and OU Health Stephenson Cancer Center to advance medical imaging research. The collaboration aims to enhance cancer detection and treatment using QT Imaging's Breast Acoustic CT™ technology. This pioneering imaging system offers quantitative imaging predictive markers to improve diagnostic precision and consistency. The University of Oklahoma's imaging center, a National Cancer Institute-designated facility, will leverage this technology in its innovative research initiatives. Furthermore, the collaboration will explore AI and ML-based algorithms to streamline clinical workflows and extract more insights from the imaging data. Dr. Javier Jo, Director at OU, and Dr. Bilal Malik, QTI’s Chief Science Officer, both emphasize the potential of this partnership to transform cancer care and develop new technological avenues in breast cancer research.

Positive

• Collaboration with prestigious University of Oklahoma and OU Health Stephenson Cancer Center.
• Use of Breast Acoustic CT™ technology with quantitative imaging predictive markers.
• Focus on advancing cancer detection and treatment.
• Development of AI/ML-based algorithms to enhance imaging insights.
• Potential to reduce subjectivity and improve diagnostic consistency.

Negative

• None.

NOVATO, Calif.--(BUSINESS WIRE)-- QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

University of Oklahoma (OU) is home to the National Cancer Institute (NCI) designated OU Health Stephenson Cancer Center (SCC), and the National Institutes of Health Center of Biomedical Research Excellence (COBRE), Oklahoma Center of Medical Imaging for Translational Cancer Research. OU’s medical imaging center recently launched its multidisciplinary biomedical research involving equipment and facilities that support project investigators in their quest to improve medical imaging use in cancer detection, diagnosis, and treatment. Innovative imaging modalities like QTI’s Breast Acoustic CT™ technology, with its quantitative imaging predictive markers, will be used to provide an objective measure or index that can reduce subjectivity and improve consistency for medical image diagnosis.

“With the help of QTI’s Breast Acoustic CT™ Scanner, we will be jumpstarting an expandable research platform meant to better understand how quantitative transmission ultrasound might advance cancer care in United States. As a translational research center, our role is to facilitate the movement of ideas between the biomedical engineering lab and the clinic, investigating how to improve cancer treatment and care,” said Dr. Javier Jo, Director of the Oklahoma Center of Medical Imaging for Translational Cancer Research at OU.

“This collaboration presents an encouraging and validating opportunity for QTI’s team to better understand the scope and potential of our technology,” said Dr. Bilal Malik, QTI’s Chief Science Officer. “In addition to exploring venues in breast cancer research with clinicians at the prestigious OU Health Stephenson Cancer Center, we look forward to collaborating with OU investigators to develop AI/ML-based algorithm tailored for our 3D images. We intend to take these algorithms through regulatory clearance pathways to ease the clinical workflows and to derive further insights from the inherently quantitative images of QTI’s technology.”

“QTI’s technology provides an unprecedented view into breast anatomy and pathology by way of acoustic computed tomography (CT) scans. We plan to incorporate QTI’s technology in our clinical research to validate its strengths, such as its ability to image frequently for disease progression as well as to be able to assess volumetric breast density without exposing the patient to radiation,” said Dr. Robert Mannel, Director of the OU Health Stephenson Cancer Center.

About QT Imaging Holding, Inc.

QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

About Oklahoma University Health Stephenson Cancer Center

OU Health Stephenson Cancer Center is Oklahoma’s only National Cancer Institute-Designated Cancer Center. Stephenson Cancer Center is one of the nation’s elite centers, representing the top 2% of cancer centers in the country. It is the largest and most comprehensive oncology practice in the state, delivering patient-centered, multidisciplinary care for every type of cancer. As one of the nation’s leading research organizations, Stephenson Cancer Center uses the latest innovations to fight and eliminate cancer. For more information, visit stephensoncancercenter.org.

About University of Oklahoma

Founded in 1890, the University of Oklahoma is a public research university located in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. OU was named the state’s highest-ranking university in U.S. News & World Report’s most recent Best Colleges list. For more information about the university, visit ou.edu.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the collaboration between QT Imaging Holdings, the University of Oklahoma Health Stephenson Cancer Center and the Oklahoma Center of Medical Imaging for Translational Cancer Research, the Breast Acoustic CT™ Scanner, plans for QT Imaging Holdings, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the Breast Acoustic CT™ Scanner, the ability of QT Imaging Holdings to sell and deploy the Breast Acoustic CT™ Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s (and its predecessor, GigCapital5, Inc.) filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624943357/en/

For media inquiries, please contact:

Susan Schaffler

Head of Communications

Susan.Schaffler@qtimaging.com

Stas Budagov

Chief Financial Officer

Stas.Budagov@qtimaging.com

Source: QT Imaging Holdings, Inc.

FAQ

What is QT Imaging Holdings' recent collaboration about?

QT Imaging Holdings has partnered with the University of Oklahoma and OU Health Stephenson Cancer Center to advance medical imaging research, particularly focusing on cancer detection and treatment.

What technology is QT Imaging Holdings using in their new research collaboration?

QT Imaging Holdings is using their Breast Acoustic CT™ technology, which offers quantitative imaging predictive markers to enhance diagnostic precision.

What are the objectives of QT Imaging Holdings' partnership with the University of Oklahoma?

The objectives include enhancing cancer detection and treatment, developing AI/ML-based algorithms for imaging data, and improving diagnostic consistency.

When was the partnership between QT Imaging Holdings and the University of Oklahoma announced?

The partnership between QT Imaging Holdings and the University of Oklahoma was announced recently, as per the latest press release.

What benefits does QT Imaging Holdings' technology provide in cancer imaging?

QT Imaging Holdings' technology provides an unprecedented view into breast anatomy without radiation exposure, allows frequent imaging for disease progression, and uses quantitative predictive markers for consistent diagnostics.